Verition Fund Management’s Korsana Biosciences, Inc. Common Stock KRSA Stock Holding History

Verition Fund Management’s Portfolio KRSA Stock Details KRSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-143	Closed	-$17K	–	2266
2022 Q3	$17K	Hold	143	–	–	﹤0.01%	2810
2022 Q2	$11K	Hold	143	–	–	﹤0.01%	2250
2022 Q1	$22K	Hold	143	–	–	﹤0.01%	2593
2021 Q4	$34K	Hold	143	–	–	﹤0.01%	2452
2021 Q3	$61K	Hold	143	–	–	﹤0.01%	1760
2021 Q2	$78K	Hold	143	–	–	﹤0.01%	1765
2021 Q1	$56K	Hold	143	–	–	﹤0.01%	1469
2020 Q4	$61K	Hold	143	–	–	﹤0.01%	1035
2020 Q3	$122K	Buy	143 +36	+34%	+$4.12K	﹤0.01%	982
2020 Q2	$89K	Hold	107	–	–	﹤0.01%	1005
2020 Q1	$40K	Buy	+107	New	+$7.63K	﹤0.01%	546

Other funds holding KRSA

SPC

Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

MFN Partners Boston, Massachusetts $4.83B AUM 65.74% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TFS

TrustCore Financial Services Brentwood, Tennessee $1.14B AUM 13.32% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Verition Fund Management's KRSA Position: Q4 2022 in Review

Verition Fund Management sold out of Korsana Biosciences, Inc. Common Stock (KRSA) in Q4 2022, closing a stake of 143 shares — an estimated $17K sold.

Verition Fund Management first reported a position in KRSA in Q1 2020 and held it in 11 quarters. The position peaked at $122K in Q3 2020. 33 funds tracked by Wall St. Rank hold KRSA as of Q4 2022.

Verition Fund Management reported no remaining Korsana Biosciences, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Verition Fund Management sold 143 Korsana Biosciences, Inc. Common Stock shares in Q4 2022, an estimated $17K.
Verition Fund Management first reported a position in Korsana Biosciences, Inc. Common Stock in Q1 2020 and held it in 11 quarters.
Verition Fund Management's Korsana Biosciences, Inc. Common Stock position peaked at $122K in Q3 2020.
33 funds tracked by Wall St. Rank held Korsana Biosciences, Inc. Common Stock as of Q4 2022.

Based on Verition Fund Management's 13F filing for Q4 2022, filed 14 Feb 2023.